A
1.49
0.12 (8.36%)
| Previous Close | 1.38 |
| Open | 1.39 |
| Volume | 396,253 |
| Avg. Volume (3M) | 879,216 |
| Market Cap | 148,988,976 |
| Price / Sales | 1.53 |
| Price / Book | 1.45 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -139.74% |
| Operating Margin (TTM) | -1,216.52% |
| Diluted EPS (TTM) | -1.26 |
| Quarterly Revenue Growth (YOY) | -76.90% |
| Total Debt/Equity (MRQ) | 43.39% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | -229.34 M |
| Levered Free Cash Flow (TTM) | -92.86 M |
| Return on Assets (TTM) | -17.22% |
| Return on Equity (TTM) | -90.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Alector, Inc. | Bullish | Bearish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.5 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.99% |
| % Held by Institutions | 80.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merck & Co., Inc. | 31 Mar 2025 | 3,545,719 |
| Euclidean Capital Llc | 31 Mar 2025 | 1,307,858 |
| 52 Weeks Range | ||
| Median | 10.00 (571.14%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 May 2025 | 10.00 (571.14%) | Buy | 1.17 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jun 2025 | Announcement | Alector Provides Executive Leadership Update |
| 03 Jun 2025 | Announcement | Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 08 May 2025 | Announcement | Alector Reports First Quarter 2025 Financial Results and Provides Business Update |
| 06 May 2025 | Announcement | Alector to Participate in Upcoming Healthcare Conferences |
| 17 Apr 2025 | Announcement | Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |